JP2011509260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509260A5 JP2011509260A5 JP2010541567A JP2010541567A JP2011509260A5 JP 2011509260 A5 JP2011509260 A5 JP 2011509260A5 JP 2010541567 A JP2010541567 A JP 2010541567A JP 2010541567 A JP2010541567 A JP 2010541567A JP 2011509260 A5 JP2011509260 A5 JP 2011509260A5
- Authority
- JP
- Japan
- Prior art keywords
- oxime
- fluorophenyl
- alkyl
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 208000002193 Pain Diseases 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- LWLNRICWXNERKX-PANOFWHVSA-N (e,e)-1-(4-fluorophenyl)-n-methoxy-2-methylpent-1-en-3-imine Chemical compound CO\N=C(/CC)\C(\C)=C\C1=CC=C(F)C=C1 LWLNRICWXNERKX-PANOFWHVSA-N 0.000 claims 2
- WBVIPJUKXQYVQJ-CHBKHGQFSA-N (ne)-n-[(e)-1-(2-fluorophenyl)-2-methylpent-1-en-3-ylidene]hydroxylamine Chemical compound CC\C(=N/O)\C(\C)=C\C1=CC=CC=C1F WBVIPJUKXQYVQJ-CHBKHGQFSA-N 0.000 claims 2
- WRDLKTQRPOZITC-QWPOMPHKSA-N (ne)-n-[(e)-1-(3,4-difluorophenyl)-2-methylpent-1-en-3-ylidene]hydroxylamine Chemical compound CC\C(=N/O)\C(\C)=C\C1=CC=C(F)C(F)=C1 WRDLKTQRPOZITC-QWPOMPHKSA-N 0.000 claims 2
- REQRXYTVHDTROQ-QWPOMPHKSA-N (ne)-n-[(e)-1-(3-chloro-4-fluorophenyl)-2-methylpent-1-en-3-ylidene]hydroxylamine Chemical compound CC\C(=N/O)\C(\C)=C\C1=CC=C(F)C(Cl)=C1 REQRXYTVHDTROQ-QWPOMPHKSA-N 0.000 claims 2
- ALDVAWDTIJSMNO-ZDHWLGKOSA-N (ne)-n-[(e)-1-(4-fluorophenyl)-2,4,4-trimethylpent-1-en-3-ylidene]hydroxylamine Chemical compound O/N=C(\C(C)(C)C)/C(/C)=C/C1=CC=C(F)C=C1 ALDVAWDTIJSMNO-ZDHWLGKOSA-N 0.000 claims 2
- KHBHURZBJBAUPN-MZRBSKCNSA-N (ne)-n-[(e)-1-(4-fluorophenyl)-2,4-dimethylpent-1-en-3-ylidene]hydroxylamine Chemical compound CC(C)\C(=N/O)\C(\C)=C\C1=CC=C(F)C=C1 KHBHURZBJBAUPN-MZRBSKCNSA-N 0.000 claims 2
- ALEGZXFLOSZQFJ-OIPGSKEASA-N (ne)-n-[(e)-1-(4-fluorophenyl)-2-methylhept-1-en-3-ylidene]hydroxylamine Chemical compound CCCC\C(=N/O)\C(\C)=C\C1=CC=C(F)C=C1 ALEGZXFLOSZQFJ-OIPGSKEASA-N 0.000 claims 2
- SSRZLDGEGHSZEF-PANOFWHVSA-N (ne)-n-[(e)-1-(4-fluorophenyl)-2-methylhex-1-en-3-ylidene]hydroxylamine Chemical compound CCC\C(=N/O)\C(\C)=C\C1=CC=C(F)C=C1 SSRZLDGEGHSZEF-PANOFWHVSA-N 0.000 claims 2
- HKROEBDHHKMNBZ-CHBKHGQFSA-N (ne)-n-[(e)-1-(4-fluorophenyl)-2-methylpent-1-en-3-ylidene]hydroxylamine Chemical compound CC\C(=N/O)\C(\C)=C\C1=CC=C(F)C=C1 HKROEBDHHKMNBZ-CHBKHGQFSA-N 0.000 claims 2
- GVMNKKDSUMTDFH-TZOAMJEDSA-N (ne)-n-[(e)-1-(4-fluorophenyl)hex-1-en-3-ylidene]hydroxylamine Chemical compound CCC\C(=N/O)\C=C\C1=CC=C(F)C=C1 GVMNKKDSUMTDFH-TZOAMJEDSA-N 0.000 claims 2
- KHBHURZBJBAUPN-MBBMFPOLSA-N (nz)-n-[(e)-1-(4-fluorophenyl)-2,4-dimethylpent-1-en-3-ylidene]hydroxylamine Chemical compound CC(C)\C(=N\O)\C(\C)=C\C1=CC=C(F)C=C1 KHBHURZBJBAUPN-MBBMFPOLSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- GLYGZIVKLCTOTJ-PGMBSLALSA-N (ne)-n-[(e)-1-(4-fluorophenyl)pent-1-en-3-ylidene]hydroxylamine Chemical compound CC\C(=N/O)\C=C\C1=CC=C(F)C=C1 GLYGZIVKLCTOTJ-PGMBSLALSA-N 0.000 claims 1
- FPMULNOOMRYVLW-UYHGDYIZSA-N (ne)-n-[(e)-2-methyl-1-(3,4,5-trifluorophenyl)pent-1-en-3-ylidene]hydroxylamine Chemical compound CC\C(=N/O)\C(\C)=C\C1=CC(F)=C(F)C(F)=C1 FPMULNOOMRYVLW-UYHGDYIZSA-N 0.000 claims 1
- APCBJCFILSRMRW-NQPRBDNZSA-N (ne)-n-[(e)-4-(4-fluorophenyl)but-3-en-2-ylidene]hydroxylamine Chemical compound O\N=C(/C)\C=C\C1=CC=C(F)C=C1 APCBJCFILSRMRW-NQPRBDNZSA-N 0.000 claims 1
- GLYGZIVKLCTOTJ-DXVMBCQGSA-N (nz)-n-[(e)-1-(4-fluorophenyl)pent-1-en-3-ylidene]hydroxylamine Chemical compound CC\C(=N\O)\C=C\C1=CC=C(F)C=C1 GLYGZIVKLCTOTJ-DXVMBCQGSA-N 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- ANIVPZHWIIHPGT-UHFFFAOYSA-N C(C)C(C=C)=NO Chemical compound C(C)C(C=C)=NO ANIVPZHWIIHPGT-UHFFFAOYSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 208000029162 bladder disease Diseases 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013990 dysuria Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000003349 osteoarthritic effect Effects 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1902108P | 2008-01-04 | 2008-01-04 | |
| PCT/US2009/030005 WO2009089082A1 (en) | 2008-01-04 | 2009-01-02 | Trpa1 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011509260A JP2011509260A (ja) | 2011-03-24 |
| JP2011509260A5 true JP2011509260A5 (enExample) | 2011-11-04 |
Family
ID=40329176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541567A Pending JP2011509260A (ja) | 2008-01-04 | 2009-01-02 | Ｔｒｐａ１アンタゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9108905B2 (enExample) |
| EP (1) | EP2249820A1 (enExample) |
| JP (1) | JP2011509260A (enExample) |
| CN (1) | CN101959511A (enExample) |
| CA (1) | CA2711408A1 (enExample) |
| MX (1) | MX2010007392A (enExample) |
| WO (1) | WO2009089082A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7951814B2 (en) * | 2008-06-17 | 2011-05-31 | Glenmark Pharmaceuticals, S.A. | Quinazolinedione derivatives as TRPA1 modulators |
| JP5847827B2 (ja) | 2010-10-12 | 2016-01-27 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Ｔｒｐａ１受容体アンタゴニスト |
| WO2012098281A2 (es) | 2011-01-19 | 2012-07-26 | Universidad Miguel Hernández De Elche | Péptidos moduladores de receptores trp y sus usos |
| EP2706995B1 (en) | 2011-05-12 | 2016-11-30 | B.R.A.I.N. Biotechnology Research and Information Network AG | Small molecule inhibitors of trpa1 |
| RU2014100744A (ru) | 2011-06-13 | 2015-07-20 | Гленмарк Фармасьютикалс С.А. | Лечение респираторных нарушений с помощью trpa1 антагонистов |
| JP2014517062A (ja) | 2011-06-22 | 2014-07-17 | グレンマーク ファーマシューティカルズ， エセ．アー． | ＴＲＰＡ１アンタゴニスト及びβ２アゴニストを含む医薬組成物 |
| WO2012176105A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist |
| US20140148423A1 (en) | 2011-07-25 | 2014-05-29 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US20140364445A1 (en) | 2011-12-05 | 2014-12-11 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent |
| MX2016004741A (es) | 2013-10-15 | 2016-07-26 | Glenmark Pharmaceuticals Sa | Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. |
| WO2016042501A1 (en) | 2014-09-16 | 2016-03-24 | Glenmark Pharmaceuticals S.A. | Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
| WO2018065288A1 (de) | 2016-10-07 | 2018-04-12 | Bayer Cropscience Aktiengesellschaft | 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz |
| TW201837026A (zh) | 2017-01-10 | 2018-10-16 | 德商拜耳廠股份有限公司 | 作為除害劑之雜環衍生物（二） |
| KR102515694B1 (ko) | 2017-01-10 | 2023-03-29 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로사이클 유도체 |
| IT202100015098A1 (it) | 2021-06-09 | 2022-12-09 | Flonext S R L | Composto antagonista del canale trpa1 per uso in patologie degenerative della retina |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834479A (en) * | 1993-03-05 | 1998-11-10 | Mayer; David J. | Method and composition for alleviating pain |
| JPH0940605A (ja) | 1995-07-26 | 1997-02-10 | Toyama Chem Co Ltd | 新規なフェニルプロピオン酸誘導体またはその塩およびそれらを含有する抗炎症剤もしくはシクロオキシゲナーゼ阻害剤 |
| BR0214967A (pt) * | 2001-12-14 | 2005-05-10 | Novo Nordisk As | Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente |
| BRPI0708153A2 (pt) * | 2006-02-21 | 2011-05-17 | Irm Llc | métodos e composições para tratar hiperalgesia |
-
2009
- 2009-01-02 WO PCT/US2009/030005 patent/WO2009089082A1/en not_active Ceased
- 2009-01-02 MX MX2010007392A patent/MX2010007392A/es unknown
- 2009-01-02 US US12/348,064 patent/US9108905B2/en not_active Expired - Fee Related
- 2009-01-02 CA CA2711408A patent/CA2711408A1/en not_active Abandoned
- 2009-01-02 EP EP09700426A patent/EP2249820A1/en not_active Withdrawn
- 2009-01-02 JP JP2010541567A patent/JP2011509260A/ja active Pending
- 2009-01-02 CN CN2009801079554A patent/CN101959511A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011508784A5 (enExample) | ||
| JP2009506117A5 (enExample) | ||
| JP2024516371A5 (enExample) | ||
| HK1211289A1 (en) | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| JP2010513478A5 (enExample) | ||
| JP2011529054A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| HRP20150119T1 (hr) | N-supstituirani derivati glicina kao inhibitori hidroksilaze | |
| JP2018518537A5 (enExample) | ||
| JP2010504343A5 (enExample) | ||
| MA38323B1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| JP2009514874A5 (enExample) | ||
| CN109906216A (zh) | 组蛋白乙酰基转移酶激活剂及其组合物和用途 | |
| JP2016513717A5 (enExample) | ||
| JP2011527333A5 (enExample) | ||
| JP2011500621A5 (enExample) | ||
| JP2014530818A5 (enExample) | ||
| JP2015522551A5 (enExample) | ||
| JP2007538094A5 (enExample) | ||
| JP2017512211A5 (enExample) | ||
| JP2018531273A5 (enExample) | ||
| JP2013523623A5 (enExample) | ||
| CL2008000554A1 (es) | Compuestos derivados de diaminopirimidina sustituida; metodo de preparacion de dichos compuestos; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad del tracto urinario, un estado patologico doloroso, un trastorno res | |
| JP2016515550A5 (enExample) |